TOP2A and cancer: These findings are consistent with earlier research, which have showed that the expression levels of TOP2A are elevated in a variety of cancers, including colorectal [49], liver [50], esophageal [51], and gastric [52], and that TOP2A may be used as a biomarker to screen out high-risk cases and forecast the prognosis of patients with malignant tumors in order to enable tailored treatment [53].